CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

PR Newswire Biotech
Original article

Keymed Biosciences anuncia los resultados del primer semestre de 2026 y novedades empresariales

EarningsNeutral
AI Analysis

Summary

Keymed Biosciences announced interim results for the first half of 2026 with total revenues of 617 million RMB as of June 30, 2026.

Financial Highlights

Revenue

617 million RMB

Importance:2/10
Sentiment:
0.00
earningsinterim resultsfirst half 2026
Related Companies

Read the original article

Published by PR Newswire Biotech on August 25, 2026 6:13 AM

Read Original